The proposal values Sage at around $442 million. A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, according to the filing.

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Zurzuvae was not approved as a treatment for major depressive disorder, as the two Cambridge drugmakers had been hoping. Biogen and Sage decided last year not pursue further development of the ...

The Cambridge, Massachusetts-based biotech added that its board of directors, along with its independent financial and legal advisors, will evaluate Biogen’s (NASDAQ:BIIB) bid and decide on the ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, with a market cap of $21.9 billion, is a leading biotechnology company specializing in developing and delivering innovative therapies.

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

CAMBRIDGE, Mass., January 10, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("The Company"), today confirmed that Biogen Inc. (Nasdaq: BIIB) ("Biogen ...